541 related articles for article (PubMed ID: 17640834)
1. Innate immune response induced by gene delivery vectors.
Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
Bessis N; GarciaCozar FJ; Boissier MC
Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
[TBL] [Abstract][Full Text] [Related]
3. Engineered adenovirus serotypes for overcoming anti-vector immunity.
Dharmapuri S; Peruzzi D; Aurisicchio L
Expert Opin Biol Ther; 2009 Oct; 9(10):1279-87. PubMed ID: 19645630
[TBL] [Abstract][Full Text] [Related]
4. Suppressive effects of sugar-modified cationic liposome/NF-kappaB decoy complexes on adenovirus vector-induced innate immune responses.
Huang H; Sakurai F; Higuchi Y; Kawakami S; Hashida M; Kawabata K; Mizuguchi H
J Control Release; 2009 Jan; 133(2):139-45. PubMed ID: 18977256
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.
Mok H; Palmer DJ; Ng P; Barry MA
Mol Ther; 2005 Jan; 11(1):66-79. PubMed ID: 15585407
[TBL] [Abstract][Full Text] [Related]
6. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex.
Sakurai H; Sakurai F; Kawabata K; Sasaki T; Koizumi N; Huang H; Tashiro K; Kurachi S; Nakagawa S; Mizuguchi H
J Control Release; 2007 Feb; 117(3):430-7. PubMed ID: 17239467
[TBL] [Abstract][Full Text] [Related]
8. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
Jooss K; Chirmule N
Gene Ther; 2003 Jun; 10(11):955-63. PubMed ID: 12756416
[TBL] [Abstract][Full Text] [Related]
9. How not to be seen: immune-evasion strategies in gene therapy.
Zaldumbide A; Hoeben RC
Gene Ther; 2008 Feb; 15(4):239-46. PubMed ID: 18046427
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of the inflammatory response to adenovirus vectors.
Liu Q; Muruve DA
Gene Ther; 2003 Jun; 10(11):935-40. PubMed ID: 12756413
[TBL] [Abstract][Full Text] [Related]
11. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.
Urosevic M; Fujii K; Calmels B; Laine E; Kobert N; Acres B; Dummer R
J Clin Invest; 2007 Oct; 117(10):2834-46. PubMed ID: 17823660
[TBL] [Abstract][Full Text] [Related]
12. Localized adenovirus gene delivery using antiviral IgG complexation.
Levy RJ; Song C; Tallapragada S; DeFelice S; Hinson JT; Vyavahare N; Connolly J; Ryan K; Li Q
Gene Ther; 2001 May; 8(9):659-67. PubMed ID: 11406760
[TBL] [Abstract][Full Text] [Related]
13. Challenges and strategies: the immune responses in gene therapy.
Zhou HS; Liu DP; Liang CC
Med Res Rev; 2004 Nov; 24(6):748-61. PubMed ID: 15250039
[TBL] [Abstract][Full Text] [Related]
14. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals.
Harvey BG; Hackett NR; Ely S; Crystal RG
Mol Ther; 2001 Feb; 3(2):206-15. PubMed ID: 11237677
[TBL] [Abstract][Full Text] [Related]
15. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.
Kiang A; Hartman ZC; Everett RS; Serra D; Jiang H; Frank MM; Amalfitano A
Mol Ther; 2006 Oct; 14(4):588-98. PubMed ID: 16733096
[TBL] [Abstract][Full Text] [Related]
16. The innate immune response to adenovirus vectors.
Muruve DA
Hum Gene Ther; 2004 Dec; 15(12):1157-66. PubMed ID: 15684693
[TBL] [Abstract][Full Text] [Related]
17. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
18. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
Schagen FH; Ossevoort M; Toes RE; Hoeben RC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
[TBL] [Abstract][Full Text] [Related]
19. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.
Appledorn DM; Kiang A; McBride A; Jiang H; Seregin S; Scott JM; Stringer R; Kousa Y; Hoban M; Frank MM; Amalfitano A
Gene Ther; 2008 Jun; 15(12):885-901. PubMed ID: 18288208
[TBL] [Abstract][Full Text] [Related]
20. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
